JLJiaxin Liu

Jiaxin Liu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Research Subjects


Jiaxin Liu has a total of 35 co-authors. Here are the top co-authors by number of shared publications:

  • Bole Tian

    West China Hospital 4 Pancreatic Division, Department of General Surgery , Chengdu, China

    1 shared publication
  • Chen Chang

    West China Hospital 1 Division of Abdominal Tumor, Department of Medical Oncology, Cancer Center and State Key Laboratory of Biological Therapy , Chengdu, China

    1 shared publication
  • Cheng Yi

    West China Hospital 1 Division of Abdominal Tumor, Department of Medical Oncology, Cancer Center and State Key Laboratory of Biological Therapy , Chengdu, China

    1 shared publication
  • Chengjian Zhao

    State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy

    1 shared publication
  • Chenyan Zhang

    West China Hospital 1 Division of Abdominal Tumor, Department of Medical Oncology, Cancer Center and State Key Laboratory of Biological Therapy , Chengdu, China

    1 shared publication
  • Dan Cao

    West China Hospital 1 Division of Abdominal Tumor, Department of Medical Oncology, Cancer Center and State Key Laboratory of Biological Therapy , Chengdu, China

    1 shared publication

Latest Publications

  • Radiotherapy Combined with Serplulimab and Chemotherapy as First-line Treatment for Metastatic Pancreatic Adenocarcinoma: A Multicenter, Single-Arm, Phase II Trial

    by Ke Cheng, Chenyan Zhang, Jiaxin Liu, Huanji Xu, Jitao Zhou, Zixing Huang, Qingqiu Wu, Yi Zhang, Ping Chen, Weikang Shao, et al.

    Purpose: The prognosis for metastatic pancreatic ductal adenocarcinoma (mPDAC) remains dismal. In this multicenter, single-arm, phase II study, we evaluated the combination of serplulimab, gemcitabine plus nab-paclitaxel (GnP), and radiotherapy (ICSBR regimen) as first-line treatment for patients with mPDAC (ChiCTR2300073237). Patients and Methods: Patients with mPDAC were enrolled in the first-line setting. The treatment regimen consisted of serplulimab and GnP administered in 21-day cycles, combined with stereotactic body radiotherapy (SBRT) directed at the primary or metastatic sites during cycle 2. Additionally, a comprehensive biomarker analysis was conducted. The primary endpoint was the 6-month progression-free survival (PFS) rate, with a predefined target of 60%. Results: Forty-six patients received at least one dose of treatment. The 6-month PFS rate was 78.3% [95% confidence interval (CI), 67.2%–91.1%]. The median PFS and overall survival (OS) were 8.5 months (95% CI, 7.3–12 months) and 14 months [95% CI, 12 months–not reached (NR)], respectively. The objective response rate (ORR) was 73.9% (95% CI, 58.9%–85.7%). The combination treatment was well tolerated, and no treatment-related deaths or unexpected safety signals were observed. Notably, patients with baseline circulating tumor DNA (ctDNA) negativity achieved a better survival. Moreover, tumor microenvironment (TME) analysis revealed that baseline fibroblast activation protein (FAP)–positive cancer-associated fibroblast (CAF) and T-cell proportions in tumor tissue correlated with clinical outcomes, with distinct spatial distribution and interaction tendencies observed among patients with different responses. Conclusions: Overall, the ICSBR regimen demonstrated a promising survival benefit as first-line treatment for mPDAC. Furthermore, ctDNA status and TME analysis highlighted potential markers for guiding precision treatment.